Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication
| Autor: | Brandie E Charles, Qintian Zheng, David L. Dawson, Sue A. Worthy, Donald V. Bradley |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Vasodilator Agents Blood viscosity Urology Tetrazoles Walking 030204 cardiovascular system & hematology Hematocrit Models Biological Pentoxifylline Placebos 03 medical and health sciences 0302 clinical medicine Double-Blind Method Erythrocyte Deformability Blood plasma medicine Humans Erythrocyte deformability Prospective Studies 030212 general & internal medicine Aged Analysis of Variance medicine.diagnostic_test business.industry Fibrinogen Intermittent Claudication Middle Aged Blood Viscosity Intermittent claudication Cilostazol Data Interpretation Statistical Anesthesia Female medicine.symptom Cardiology and Cardiovascular Medicine Claudication business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Angiology. 53:509-520 |
| ISSN: | 1940-1574 0003-3197 |
| DOI: | 10.1177/000331970205300503 |
| Popis: | Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deformability have been cited as potential mechanisms of action for pentoxifylline. Cilostazol is a new drug with antiplatelet and vasodilating activity, but the mechanism by which it promotes an improvement in walking is not known. This study was performed to evaluate and compare the hemorheologic effects of pentoxifylline and cilostazol on viscosity, fibrinogen levels, and erythrocyte deformability when administered to adults with moderate to severe claudication. A double-blind, controlled study was conducted and included 59 patients (46 male, 13 female; mean age 65 yr) randomized to pentoxifylline 400 mg orally thrice daily (n=20), cilostazol 100 mg orally twice daily (n=19), or placebo (n=20); all subjects were observed for 24 weeks. Walking ability was assessed before, during, and at the conclusion of treatment by standard constant speed, variable grade treadmill testing. Erythrocyte deformability was measured by passage of washed RBCs, 10% hematocrit in phosphate buffered saline (PBS), through a polycarbonate membrane with 4.7 to 5.0 microm pores. Whole blood and plasma viscosity were measured using a cone/plate viscometer at variable shear rates (from 4.5 to 450 sec(-1)). Erythrocyte sedimentation rate was measured by a modified Westergren technique. Fibrinogen was assayed by a commercial reference laboratory. Plasma viscosities did not change significantly in any treatment group. Within-group comparisons demonstrated a significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|